Research map: Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics

Back to the article

Papers in this map

  1. Death Receptors: Signaling and Modulation · Avi Ashkenazi · 1998 · 5896 citations · Cited by this paper
  2. Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling · Lotte Habermann-Horstmeier · 2026 · 1 citation · Related
  3. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. · Ludwig A. Sternberger · 1983 · 1170 citations · Cited by this paper
  4. Mechanisms and functions of the TRIM protein family in digestive system cancers · 2026 · Related
  5. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses · Lindsay K. Ward-Kavanagh · 2016 · 485 citations · Cited by this paper
  6. Deep N-glycoproteomic profiling of FFPE tissues enables precise diagnosis of primary liver cancer from metastatic liver cancer · 2026 · Related
  7. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy · Sarah L. Buchan · 2017 · 307 citations · Cited by this paper
  8. Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity · 2026 · Related
  9. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia · Tian Lan · 2017 · 264 citations · Cited by this paper
  10. Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting · 2026 · Related
  11. Cancer therapy with antibodies · Suman Paul · 2024 · 249 citations · Cited by this paper
  12. Methionine addiction in oral squamous cell carcinoma: a metabolic vulnerability targeted by engineered bacteria · 2026 · Related
  13. CD28/CTLA-4 and CD80/CD86 families · Jacqueline M. Slavik · 1999 · 197 citations · Cited by this paper
  14. Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling · 2026 · Related
  15. Bispecific antibodies: advancing precision oncology · Mercedes Herrera · 2024 · 179 citations · Cited by this paper
  16. Precision hyperbaric oxygen therapy: a biomarker-driven framework · 2026 · Related
  17. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab · Sherman Michael Chin · 2018 · 151 citations · Cited by this paper
  18. Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety · 2026 · Related
  19. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy · Atsushi Yonezawa · 2015 · 141 citations · Cited by this paper
  20. BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings · 2026 · Related
  21. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade · Cecile A. W. Geuijen · 2021 · 118 citations · Cited by this paper
  22. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity · Sarah L. Buchan · 2018 · 115 citations · Cited by this paper
  23. CD70–CD27 interactions provide survival and proliferative signals that regulate T cell receptor‐driven activation of human γδ peripheral blood lymphocytes · Ana deBarros · 2010 · 104 citations · Cited by this paper
  24. Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27–Transgenic Mice · Li-Zhen He · 2013 · 103 citations · Cited by this paper
  25. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans · Amos Baruch · 2020 · 94 citations · Cited by this paper
  26. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy · Ran Salomon · 2022 · 81 citations · Cited by this paper
  27. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy · Agathe Dubuisson · 2017 · 80 citations · Cited by this paper
  28. Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy · Seongju Jeong · 2020 · 79 citations · Cited by this paper
  29. Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity · Eva Sum · 2021 · 72 citations · Cited by this paper
  30. The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy · Wen Deng · 2024 · 70 citations · Cited by this paper
  31. Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia · Laura A. Vitale · 2012 · 69 citations · Cited by this paper
  32. Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies · Kendra K. Radtke · 2024 · 64 citations · Cited by this paper
  33. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement · Miguel A. Gaspar · 2020 · 59 citations · Cited by this paper
  34. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity · Shiming Ye · 2019 · 58 citations · Cited by this paper
  35. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho · Alexandra S. Aaldijk · 2023 · 58 citations · Cited by this paper
  36. Harnessing the potential of CD40 agonism in cancer therapy · Yang Zhou · 2023 · 57 citations · Cited by this paper
  37. Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist · Juan Manuel García‐Martínez · 2020 · 45 citations · Cited by this paper
  38. Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions. · S E Stark · 1991 · 43 citations · Cited by this paper
  39. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy · Johannes Sam · 2024 · 42 citations · Cited by this paper

Source: OpenAlex (CC0)